YOUR LEGAL SUPPORT STARTS HERE.
OZEMPIC LEGAL LAWSUIT
Take the first step towards seeking justice. Click below to schedule a consultation and explore your legal options.
STANDING STRONG TOGETHER:
ADVOCATING FOR THOSE INJURED BY OZEMPIC INJECTION
DO I HAVE A CASE?
FINDING OUT IS QUICK AND EASY
Have You Experienced Side Effects from Ozempic or Wegovy? You're Not Alone!
You might have been drawn to Ozempic or Wegovy, initially developed as diabetes medications, due to their recent rise in popularity as weight loss solutions. Promoted by celebrity endorsements and numerous positive testimonials, these drugs have been praised for their apparent efficacy.
However, with a broader usage base, an increasing number of concerning side effects have emerged. A report from CNN brought to light alarming incidents of persistent vomiting related to a condition known as gastroparesis. This disorder interrupts the normal passage of food from the stomach to the intestines, leading to symptoms such as abdominal discomfort, bloating, nausea, and severe vomiting.
One individual on Ozempic had to take significant time off work due to these side effects. After starting the medication in 2018, she experienced both weight loss and these severe symptoms. The U.S. Food and Drug Administration has also noted similar concerns from others. Further, the American Society of Anesthesiologists recently advised patients to halt these medications at least a week before elective surgery.
The active component in these drugs, semaglutide, falls under glucagon-like peptide-1 (GLP-1) receptor agonists. While effective in producing a feeling of fullness by slowing stomach emptying, clinical trials indicate they may induce gastroparesis symptoms.
In response to these concerns, the drugmaker, Novo Nordisk, highlighted the drug's safety as evidenced by clinical and real-world studies. They acknowledged gastrointestinal side effects as a known result of the GLP-1 class, emphasizing that most are mild to moderate in nature.
If you or a loved one has experienced these or other side effects after using Ozempic or Wegovy, you might be eligible to join a mass tort lawsuit. Seek justice and compensation for any undue harm or suffering. Join our community in holding responsible parties accountable.
Time line latest update
Recent Developments in Ozempic Lawsuits
Ozempic, a medication containing semaglutide and manufactured by Novo Nordisk, has garnered legal attention. Jaclyn Bjorklund initiated the first lawsuit against Ozempic, also involving the drug Mounjaro (tirzepatide) and its manufacturer, Eli Lilly. These lawsuits are still in their early phases, with no global settlements or jury trials concluded as of yet.
As of February 2024, there have been no class-action lawsuits in the U.S. concerning Ozempic aimed at seeking refunds for the drug. However, legal representatives are actively pursuing personal injury lawsuits related to conditions such as gastroparesis, ileus, and intestinal blockage or obstruction. Additionally, a separate litigation involving Ozempic patents has seven pending cases in the multidistrict litigation (MDL)
Ozempic Lawsuit Timeline
March 2024:
Litigation is still in the early stages. Attorneys for defendants Novo Nordisk and Eli Lilly filed their notices of appearance and more plaintiffs continue to transfer into the MDL.
February 2024:
At least 55 lawsuits claiming Ozempic and other GLP-1 RAS class drugs caused severe gastrointestinal injuries were combined into a federal multidistrict litigation in the Eastern District of Pensylvania. Plaintiff's lawyers expected the number could grow to as many as 10,000.
January 2024:
The FDA said it was evaluating reports of hair loss, suicidal thoughts and aspiration under sedation and anesthesia among people taking Ozempic and similar diabetes and weight loss medications. The move followed multiple reports of the possible side effects received in the FDA Adverse Event Reporting System database.
December 2023:
Judge James Cain, Jr. denied Novo Nordisk's attempt to dismiss Jaclyn Bjorklund's case. He did dismiss the express warranty claims. All other claims, including failure to warn, are clear to proceed. Plaintiff lawyers filed a motion to consolidate Ozempic cases in Louisiana District Court.
November 2023:
Canadians filed a proposed class action lawsuit in B.C. Supreme Court alleging Novo Nordisk failed to adequately warn prospective patients about potential complications, specifically gastroparesis, linked to Ozempic. This lawsuit mirrors similar legal actions elsewhere.
September 2023:
FDA added intestinal blockage/obstruction and ileus to Ozempic's warning label.
August 2023:
Jaclyn Bjorklund, 2:23-cv-01020-JDC-KK, became one of the first people to file an Ozempic and Mounjaro gastroparesis lawsuit. Summonses to Novo Nordisk and Eli Lilly were issued on Aug. 3. Three months later, on Nov. 3, 2023, Novo Nordisk filed a motion to dismiss Bjorklund's lawsuit in Louisiana federal court.
July 2023:
ASHP, the largest association of pharmacy professionals in the U.S., advised that Novo Nordisk was running short of Ozempic and Wegovy, another semaglutide, because of increased demand.
August 2022:
Judges centralized seven Novo Nordisk lawsuits in multidistrict litigation in Delaware against generic drug makers for patent infringement. Defendants had filed U.S. Food and Drug Administration applications for approval to make generic versions of Ozempic. Also in August, after scientists published a research letter in JAMA Internal Medicine linking Ozempic to a higher risk of gallbladder disease and gallstones, lawyers began accepting Ozempic gallbladder lawsuits.